Stock Report

Download full stock data and analysis for free Last Updated: 04-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Taro Pharmaceutical - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$42.97

$0.00 (0.00%)

As on 21-Jun-2024 19:00EDT

Market cap

info icon

$1,615 Mln

Revenue (TTM)

info icon

$629 Mln

P/E Ratio

info icon

30

P/B Ratio

info icon

0.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 4.96 12.52 9.81 4.65 -1.25
EBIT -37.50 6.11 -36.24 -68.44 -38.95
Net Profit -25.39 118.11 111.70 28.62 -29.24
EPS -25.39 118.11 111.70 28.90 -27.64
Book Value -- -- 3.59 2.15 -0.71
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsMar-24Mar-23Mar-22
EBIT-Margin info 13.1241.183.423.0932.84
Net Margin info ----------
Return on equity info 2.65-0.183.061.483.41
Return on Capital info 2.65-0.183.061.483.41
Return on Assets info 2.080.052.511.182.54
Debt to Equity (x) info ------0.000.00

Profitability

View Detailed Peer Comparison

ROCE

3.06

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
3.06
1.48
3.41
-21.03
12.18
Peer Median
--
--
--
--
--
ROE

3.06

--

Profit after tax / Average Net worth * 100

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
3.06
1.48
3.41
-21.05
12.18
Peer Median
--
--
--
--
--
ROA

2.51

--

Profit after tax / Average Total assets * 100

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
2.51
1.18
2.54
-16.88
10.91
Peer Median
--
--
--
--
--
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
3.09
32.84
128.32
38.24
Peer Median
--
--
--
--
--
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
4.44
10.38
-73.00
37.88
Peer Median
--
--
--
--
--

Growth

View Detailed Peer Comparison

Revenue Growth

0.10

--

Year on year growth in net sales

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
0.10
0.02
0.02
-0.15
-0.04
Peer Median
--
--
--
--
--
EBIT Growth

--

--

Year on year growth in operating profit (EBIT)

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
-90.39
-73.83
185.74
-6.45
Peer Median
--
--
--
--
--
Net Profit Growth

111.70

--

Year on year growth in profit after tax

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
111.70
-56.33
114.54
-264.08
-13.32
Peer Median
--
--
--
--
--
EPS Growth

1.12

--

Year on year growth in earnings per share

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
1.12
-0.56
1.15
-2.65
-0.13
Peer Median
--
--
--
--
--

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
0.00
0.00
0.00
0.00
Peer Median
--
--
--
--
--
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
0.00
0.00
0.00
0.00
Peer Median
--
--
--
--
--
Current Ratio

3.61

--

Current Assets / Current Liabilities and Provisions

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
3.61
3.47
3.10
2.17
6.88
Peer Median
--
--
--
--
--
Quick Ratio

3.04

--

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
3.04
2.88
2.61
1.91
6.19
Peer Median
--
--
--
--
--
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
1.00
111.53
516.83
340.05
Peer Median
--
--
--
--
--

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
--
45.29
54.64
48.62
42.00
Peer Median
--
--
--
--
--
Asset Turnover

0.29

--

Sales / Average Total Assets

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
0.29
0.27
0.24
0.23
0.29
Peer Median
--
--
--
--
--
Receivable days

126.82

--

Average Debtors / Sales * 365

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
126.82
180.46
186.61
178.87
157.51
Peer Median
--
--
--
--
--
Inventory Days

243.06

--

Average Inventory / Sales * 365

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
243.06
262.05
266.04
241.29
224.44
Peer Median
--
--
--
--
--
Payable days

63.74

--

Average Creditors / Cost of goods sold * 365

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
63.74
81.96
88.10
65.16
47.64
Peer Median
--
--
--
--
--
Cash Conversion Cycle

306.14

--

Receivable Days + Inventory Days - Payable Days

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
306.14
360.55
364.54
355.00
334.31
Peer Median
--
--
--
--
--

Valuation

View Detailed Peer Comparison

Price / Earnings

29.54

--

Current share price divided by earning per share in the last twelve months

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
29.54
35.92
27.91
-7.01
9.59
Peer Median
--
--
--
--
--
Price / Book Value

0.89

--

Current share price divided by book value per share in the latest financial year

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
0.89
0.53
0.95
1.65
1.11
Peer Median
--
--
--
--
--
EV/EBITDA

13.54

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
Mar-24
Mar-23
Mar-22
Mar-21
Mar-20
Taro Pharmaceutical - ADR
13.54
1.25
3.84
2.45
4.88
Peer Median
--
--
--
--
--
loading...
loading...